Tamoxifen reduces plasma homocysteine levels in healthy women

Cattaneo, Marco; Baglietto, Laura; Zighetti, Maddalena L.; Bettega, Donato; Robertson, Chris; Costa, Alberto; Mannucci, Pier Mannuccio; DeCensi, Andrea

doi:10.1038/bjc.1998.376

Cited by 47 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with previous reports [9,10], we observed that tamoxifen therapy was associated with the lowering of serum homocysteine levels, but these changes were not significant. Although the number of our study subjects was small, from our results, we might surmise that tamoxifen treatment does not significantly influence serum homocysteine levels.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The effects of tamoxifen on homocysteine levels in breast cancer patients

Eroğlu¹,

Eğin

Akar

2009

Open Medicine

View full text Add to dashboard Cite

AbstractTamoxifen is widely used in the treatment of breast cancer and associated with an increased risk of thromboembolism (TE). An elevated homocysteine is one of the risk factors for TE. The aim of the study was to assess the effect of tamoxifen on serum homocysteine levels in breast cancer patients. We performed a case-control study in 20 female subjects to evaluate the relationship between homocysteine levels, and 5,10-methylenetetrahyrofolate reductase (MTHFR) C677T and dihydrofolate reductase (DHFR) 19-bp intron-1 deletion polymorphisms in breast cancer patients and in control subjects. It was observed that homocysteine levels were decreased during tamoxifen therapy, but this finding was not statistically significant. There was also no statistically significant difference in homocysteine levels between the two groups (p> 0.05). MTHFR C677T and DHFR 19-bp deletion polymorphisms were not associated with serum homocysteine value in either group.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Moreover, the results have been conflicting, and important alterations have not been identified [7][8][9][10]. Previously, we indicated that the risk of TE during tamoxifen therapy was increased in breast cancer patients with factor V Leiden mutation [11].…”

Section: Discussionmentioning

confidence: 97%

The effects of tamoxifen on homocysteine levels in breast cancer patients

Eroğlu¹,

Eğin

Akar

2009

Open Medicine

View full text Add to dashboard Cite

show abstract

“…Possible mechanisms include the effect of SERMs on lipids, vascular endothelium, insulin-like growth factor-I, and homocysteine. [25][26][27][28][29] For two reasons, women with a history of breast carcinoma may be at a lower risk of developing CHD than women without a history of breast carcinoma. First, estrogens may be etiologic in the development of breast carcinoma and protective of CHD.…”

mentioning

confidence: 99%

Favorable cardiac risk among elderly breast carcinoma survivors

Lamont

Christakis

Lauderdale

2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDThere are two reasons why women who survive breast carcinoma may be at a lower risk of developing coronary heart disease (CHD) compared with women without a history of breast carcinoma. First, estrogens may be etiologic in the development of breast carcinoma and protective of CHD. Second, a common therapy for breast carcinoma (tamoxifen) may be associated with cardiac protection.METHODSIn this population‐level cohort study, the authors analyzed data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)‐Medicare program to study the cardiac risk of elderly female Medicare beneficiaries with and without a history of breast carcinoma. Using the SEER file, the authors identified elderly women survivors of Stage 0, I, or II breast carcinoma (n = 5980) diagnosed between the ages of 55 and 64. Using the Medicare 5% noncancer file, the authors also identified elderly women without a history of cancer (n = 23,165). They followed women from age 67 for up to 5 years for hospitalization for acute myocardial infarction (AMI) through a review of Medicare claims. The authors controlled the analyses for race, socioeconomic status, geographic location, cohort entry year, and medical comorbidity.RESULTSThe hazard of hospitalization for AMI for breast carcinoma survivors relative to comparison patients was 0.66 (95% confidence interval, 0.49–0.88). This apparent cardioprotective effect of breast carcinoma survivorship was stronger in breast carcinoma survivors with documented cardiac risk factors.CONCLUSIONSSurvivors of early‐stage postmenopausal breast carcinoma are at a significantly lower risk of hospitalization for AMI than women who do not have a history of breast carcinoma. That survivors' risk varies with previous cardiac risk factors may be consistent with effects of selective estrogen receptor modulators. This phenomenon should be evaluated further with individual‐level data containing information on patient cardiac risk factors and tamoxifen use to help clarify the mechanism behind the risk reduction. Cancer 2003;98:2–10. © 2003 American Cancer Society.DOI 10.1002/cncr.11467

show abstract

“…6 Tamoxifen has several favorable antiatherosclerotic properties. [7][8][9][10][11] Data from several breast cancer trials, [12][13][14] but not all, 15 have suggested that tamoxifen may reduce cardiac events in women.…”

mentioning

confidence: 99%

Influence of Tamoxifen on Carotid Intima-Media Thickness in Postmenopausal Women

et al. 2002

View full text Add to dashboard Cite

Background-Intima-media thickness of the common carotid artery (IMT-CCA) is an early marker of atherosclerosis.Tamoxifen is a selective estrogen-receptor modulator with estrogen-like effects on cardiovascular risk factors but as-yet unexplored effects on carotid artery structure. The goal of this study was to determine the influence of tamoxifen on IMT-CCA in menopausal women. Methods and Results-With a predefined calculation of the sample size, 67 menopausal women with cancer who were treated with tamoxifen for Ն1 year and 37 menopausal women with cancer who were never treated with tamoxifen were enrolled. IMT-CCA, internal diameter, and pulse pressure were determined with a high-definition echotracking device and applanation tonometry in a central core laboratory that was blinded to treatment. Both groups were similar for clinical characteristics, including cardiovascular risk factors. IMT and internal diameter were significantly lower in the tamoxifen group (mean duration of treatment, 2.4Ϯ0.9 years) than in the control group (609Ϯ117 m versus 662Ϯ147 m, Pϭ0.04, and 4.89Ϯ0.60 mm versus 5.12Ϯ0.58 mm, Pϭ0.03, respectively). Pulse pressure was not influenced by the use of tamoxifen. After adjustment for age, cardiovascular risk factors, carotid pulse pressure, duration of menopause, and previous use of hormone replacement therapy, IMT remained significantly lower among tamoxifen users (PϽ0.00001), with an impact on IMT (Ϫ70 m) equivalent to spontaneous evolution with 12 years of aging (5 m/y). Conclusion-The use of tamoxifen was associated with a significantly lower carotid IMT in menopausal women with cancer. Randomized trials are needed to confirm the cardioprotective effect of selective estrogen-receptor modulators in terms of prevention of atherosclerosis.

show abstract

Tamoxifen reduces plasma homocysteine levels in healthy women

Cited by 47 publications

References 28 publications

The effects of tamoxifen on homocysteine levels in breast cancer patients

The effects of tamoxifen on homocysteine levels in breast cancer patients

Favorable cardiac risk among elderly breast carcinoma survivors

Influence of Tamoxifen on Carotid Intima-Media Thickness in Postmenopausal Women

Contact Info

Product

Resources

About